CRSP · Insider Trading
CRISPR Therapeutics AG
Every open-market purchase and sale reported by CRSP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | Andrew Jacob Silver | Chief Financial Officer | A | +25,000 deriv. | — |
| 2026-10-20 | Samarth Kulkarni | Chief Executive Officer | MIXED | +52,163 | −$2.38M |
| 2026-10-16 | Simeon George | Director | MIXED | +15,486 | −$300.37K |
| 2026-10-15 | Samarth Kulkarni | Chief Executive Officer | MIXED | +4,235 | −$201.87K |
| 2026-10-15 | James R. Kasinger | General Counsel and Secretary | MIXED | +1,073 | −$51.23K |
| 2026-10-08 | James R. Kasinger | General Counsel and Secretary | MIXED | — | −$92.38K |
| 2026-09-24 | James R. Kasinger | General Counsel and Secretary | MIXED | — | −$484.81K |
| 2026-09-21 | Ali Behbahani | Director | J | +75 | — |
| 2026-09-21 | Ali Behbahani | Director | MIXED | +16,321 | −$360.94K |
| 2026-08-11 | Raju Prasad | Chief Financial Officer | G | −750 | — |
| 2026-06-09 | Simeon George | Director | A | +13,000 deriv. | — |
| 2026-06-09 | Sandesh Mahatme | Director | A | +13,000 deriv. | — |
| 2026-06-09 | Maria Fardis | Director | A | +13,000 deriv. | — |
| 2026-06-09 | Christian Rommel | Director | A | +13,000 deriv. | — |
| 2026-06-09 | Katherine A High | Director | A | +13,000 deriv. | — |
| 2026-06-09 | Briggs Morrison | Director | A | +13,000 deriv. | — |
| 2026-06-09 | Douglas A Treco | Director | A | +13,000 deriv. | — |
| 2026-06-09 | Ali Behbahani | Director | A | +13,000 deriv. | — |
| 2026-06-09 | Harold Edward Fleming | Director | A | +13,000 deriv. | — |
| 2026-06-09 | John Greene | Director | A | +13,000 deriv. | — |
| 2026-06-02 | Naimish Patel | Chief Medical Officer | A | +22,000 deriv. | — |
| 2026-06-02 | James R. Kasinger | General Counsel and Secretary | A | +17,000 deriv. | — |
| 2026-06-02 | Raju Prasad | Chief Financial Officer | A | +19,500 deriv. | — |
| 2026-06-01 | Naimish Patel | Chief Medical Officer | MIXED | +6,214 | −$210.58K |
| 2026-03-24 | Naimish Patel | Chief Medical Officer | A | +68,499 deriv. | — |
| 2026-03-24 | James R. Kasinger | General Counsel and Secretary | MIXED | +3,068 | −$148.85K |
| 2026-03-24 | Raju Prasad | Chief Financial Officer | MIXED | +2,542 | −$173.46K |
| 2026-03-24 | Samarth Kulkarni | Chief Executive Officer | MIXED | +9,667 | −$468.74K |
| 2026-03-17 | James R. Kasinger | General Counsel and Secretary | MIXED | +3,425 | −$166.50K |
| 2026-03-17 | Samarth Kulkarni | Chief Executive Officer | MIXED | +10,276 | −$499.44K |
| 2026-03-17 | Naimish Patel | Chief Medical Officer | MIXED | +4,975 | −$152.02K |
| 2026-03-17 | Raju Prasad | Chief Financial Officer | MIXED | +6,256 | −$476.28K |
| 2026-03-12 | Samarth Kulkarni | Chief Executive Officer | MIXED | +9,452 | −$517.33K |
| 2026-03-12 | James R. Kasinger | General Counsel and Secretary | MIXED | +2,700 | −$147.84K |
| 2026-02-20 | Samarth Kulkarni | Chief Executive Officer | MIXED | +6,283 | −$366.32K |
| 2026-02-20 | James R. Kasinger | General Counsel and Secretary | MIXED | +1,713 | −$111.05K |
| 2026-01-27 | Naimish Patel | Chief Medical Officer | Buy | +1,508 | +$49.70K |
| 2026-01-26 | Raju Prasad | Chief Financial Officer | MIXED | — | −$525.98K |
| 2026-01-22 | Samarth Kulkarni | Chief Executive Officer | Sell | −90,000 | −$5.17M |
| 2026-01-08 | Raju Prasad | Chief Financial Officer | MIXED | — | −$451.01K |
| 2025-12-23 | Raju Prasad | Chief Financial Officer | Sell | −10,000 | −$559.55K |
| 2025-12-22 | Samarth Kulkarni | Chief Executive Officer | G | −30,000 | — |
| 2025-10-20 | Samarth Kulkarni | Chief Executive Officer | MIXED | +49,105 | −$3.46M |
| 2025-10-15 | James R. Kasinger | General Counsel and Secretary | MIXED | +1,038 | −$71.66K |
| 2025-10-15 | Samarth Kulkarni | Chief Executive Officer | MIXED | +4,092 | −$282.52K |
| 2025-10-03 | Samarth Kulkarni | Chief Executive Officer | A | +49,500 deriv. | — |
| 2025-10-03 | James R. Kasinger | General Counsel and Secretary | A | +16,500 deriv. | — |
| 2025-10-03 | Naimish Patel | Chief Medical Officer | A | +16,500 deriv. | — |
| 2025-10-03 | Raju Prasad | Chief Financial Officer | A | +16,500 deriv. | — |
| 2025-09-19 | Samarth Kulkarni | Chief Executive Officer | G | −6,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 445,358 | $22.92M |
| James R. Kasinger | General Counsel and Secretary | 95,857 | $4.93M |
| Simeon George | Director | 85,173 | $4.38M |
| Douglas A Treco | Director | 22,000 | $1.13M |
| Naimish Patel | Chief Medical Officer | 19,357 | $996.30K |
| Julianne Bruno | Chief Operating Officer | 19,346 | $995.74K |
| Ali Behbahani | Director | 16,666 | $857.80K |
| Raju Prasad | Chief Financial Officer | 14,815 | $762.53K |
| John Greene | Director | 7,000 | $360.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRSP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.